Astellas Pharma, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • Advanced Cell Technology
  • Agensys
  • Audentes Therapeutics
  • Fujisawa
  • Ganymed Pharmaceuticals
  • Iota Biosciences
  • Iveric Bio
  • Mytogen
  • Nanna Therapeutics
  • Perseid Therapeutics
  • Potenza Therapeutics
  • Ocata Therapeutics
  • OSI Pharmaceuticals
  • Yamanouchi Pharmaceutical
  • Ogeda
  • Mitobridge
  • Mitokyne
  • Quethera
  • Universal Cells
  • Xyphos Biosciences
  • Astellas Pharma Malaysia
  • Astellas Pharma Singapore
  • Astellas Institute for Regenerative Medicine
  • Propella
See more in Biomedtracker

Latest on Astellas Pharma, Inc.

Scrip

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

As Menarini builds out its “glocalized” portfolio strategy to propel its business in the Asia-Pacific, the Italian group is also advancing efforts in digital innovation and leveraging real-world evide

Scrip

Pipeline Growth Slowed In 2024 But Oncology And Neurologicals Held Strong

 
• By Alexandra Shimmings

The number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure

Scrip

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

 
• By Alaric DeArment

Who: Sangamo Therapeutics/Eli Lilly What: Lilly signed a deal with Sangamo to license the gene therapy company’s STAC-BBB adeno-associated viral vector capsid for up to five potential neurological

Scrip

Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity

 
• By Jessica Merrill

Corcept Therapeutics’ cortisol modulator relacorilant improved progression-free survival (PFS) and overall survival (OS) in a Phase III trial in patients with platinum-resistant ovarian cancer, paving